RxDoctor Payments Data

Marc Rhodes, APRN

Family · Augusta, GANPI 1487865754

Payments from drug & device makers

$1,832in general payments, 2019–2025

Across 63 payments — averaging $29.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$402
  • AstraZeneca$289
  • Novartis$201
  • Amgen$190
  • Vital Connect, Inc$153
  • Cardiva Medical, Inc.$92
  • plus $505 from 15 others

What the payments were for

  • Food & beverage$1,73295%
  • Education$1005%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,832 in reported general payments places this provider in the 75th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$13,224
Medicare patients
144
Services billed
205

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan67$59,707
EliquisApixaban63$54,061
XareltoRivaroxaban18$26,369
JardianceEmpagliflozin27$20,640
ClopidogrelClopidogrel Bisulfate209$3,190
Candesartan Cilexetil32$2,675
Metoprolol Succinate127$1,801
Rosuvastatin Calcium133$1,537
Atorvastatin Calcium113$1,401
Eplerenone14$1,375
Carvedilol127$1,269
Ezetimibe87$1,234
Spironolactone122$996
Isosorbide Dinitrate12$857
Ranolazine ErRanolazine20$748

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$201$59,70767 claims
PfizerEliquis$65$54,06163 claims
Johnson & JohnsonXarelto$44$26,36918 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 6,258 family providers in Georgia.

Other family in Augusta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →